Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.72 +1.1%	$3.63	$1.07 ▼ $4.08	$967.81M	0.96	3.02 million shs	3.02 million shs
ANNX Annexon	$2.45 +2.1%	$2.47	$1.28 ▼ $7.85	$263.32M	1.3	1.71 million shs	871,731 shs
GHRS GH Research	$13.74 -4.3%	$13.82	$6.00 ▼ $20.50	$747.12M	0.97	350,928 shs	273,409 shs
SANA Sana Biotechnology	$3.91 -3.7%	$3.33	$1.26 ▼ $7.30	$915.43M	1.9	5.42 million shs	4.05 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+1.09%	+4.49%	+2.48%	+51.84%	+169.57%
ANNX Annexon	+2.08%	-2.39%	-12.81%	+24.37%	-61.78%
GHRS GH Research	-4.32%	-5.24%	-8.58%	+20.63%	+10.81%
SANA Sana Biotechnology	-3.69%	-21.01%	+33.90%	+106.88%	-35.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.7291 of 5 stars	3.6	2.0	4.0	1.8	0.8	0.6
ANNX Annexon	1.8289 of 5 stars	3.5	1.0	0.0	0.6	2.5	0.6
GHRS GH Research	2.2794 of 5 stars	3.5	2.0	0.0	2.4	2.5	0.0
SANA Sana Biotechnology	3.1785 of 5 stars	3.5	3.0	0.0	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	81.45% Upside
ANNX Annexon	3.00	Buy	$12.50	410.20% Upside
GHRS GH Research	3.00	Buy	$32.00	132.90% Upside
SANA Sana Biotechnology	3.00	Buy	$9.17	134.44% Upside

Current Analyst Ratings Breakdown

Latest ANNX, GHRS, AKBA, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/14/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $14.00
5/13/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $11.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.10	N/A	N/A	($0.23) per share	-16.17
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/7/2025 (Estimated)
ANNX Annexon	-$138.20M	-$1.18	N/A	N/A	N/A	N/A	-54.45%	-46.56%	8/11/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest ANNX, GHRS, AKBA, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ANNX Annexon	-$0.36	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AKBA Akebia Therapeutics	-$0.02	N/A	N/A	N/A	$47.60 million	N/A
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	-$0.37	-$0.07	-$0.37	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
ANNX Annexon	N/A	7.99	7.99
GHRS GH Research	N/A	29.71	29.71
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ANNX Annexon	N/A
GHRS GH Research	56.90%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
ANNX Annexon	11.87%
GHRS GH Research	41.60%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ANNX Annexon	60	109.71 million	96.69 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable

ANNX, GHRS, AKBA, and SANA Headlines

Recent News About These Companies

Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects

August 1 at 7:42 AM | insidermonkey.com

Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects

August 1 at 7:06 AM | finance.yahoo.com

Citi Remains Bullish on Sana Biotechnology (SANA)

August 1 at 2:06 AM | msn.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 6.7% - Should You Sell?

July 30 at 1:16 PM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Skandinaviska Enskilda Banken AB publ

July 30 at 5:27 AM | marketbeat.com

World-first obesity pill reprograms fat cells to burn calories with zero effort

July 23, 2025 | newatlas.comN

Citi Maintained a Buy Rating on Sana Biotechnology (SANA)

July 23, 2025 | msn.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.7% - Here's What Happened

July 21, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley

July 11, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Up - Here's Why

July 9, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 14.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting

July 4, 2025 | msn.com

Sana Biotechnology (NASDAQ:SANA) Coverage Initiated by Analysts at Morgan Stanley

July 3, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.6% - What's Next?

July 2, 2025 | marketbeat.com

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results

June 29, 2025 | insidermonkey.com

Sana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.com

June 26, 2025 | investing.com

Sana Biotechnology (SANA) Receives a Buy from Citizens JMP

June 26, 2025 | theglobeandmail.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24, 2025 | insidermonkey.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23, 2025 | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, GHRS, AKBA, and SANA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.72 +0.04 (+1.09%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.74 +0.02 (+0.54%)

As of 08/1/2025 07:47 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Annexon NASDAQ:ANNX

$2.45 +0.05 (+2.08%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.58 +0.13 (+5.31%)

As of 08/1/2025 07:54 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

GH Research NASDAQ:GHRS

$13.74 -0.62 (-4.32%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.72 -0.03 (-0.18%)

As of 08/1/2025 06:38 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Sana Biotechnology NASDAQ:SANA

$3.91 -0.15 (-3.69%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.97 +0.06 (+1.53%)

As of 08/1/2025 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time